Nevertheless, as multiple clinical trials investigating different TIGIT antibodies are ongoing, we will obtain comprehensive data in the future in order to determine which TIGIT antibody acts most efficiently in head and neck cancer patients and even more in the subgroup of OSCC. The gene discussed is TIGIT; the disease is head and neck cancer.